Caldwell B V
Department of Medicine, Yale New Haven Hospital, Connecticut.
Clin Ther. 1993 Jul-Aug;15(4):618-36; discussion 617.
Although many drugs effectively control hypertension in patients with diabetes mellitus, the risk of aggravating the diabetic process and inducing new complications can negate the benefits of reduced blood pressure. This article discusses the current status of antihypertensive therapy in diabetic patients and focuses on the use of calcium channel blockers that safely reduce blood pressure while having a neutral or beneficial effect on the diabetic state and related medical complications. While both calcium channel blockers and angiotensin-converting enzyme (ACE) inhibitors are suitable agents for the primary treatment of diabetic hypertension, the beneficial effects of calcium channel blockers on glucose homeostasis, lipid metabolism, and renal function support their routine use as alternatives to ACE inhibitors. Among the three classes of calcium channel blockers, second-generation dihydropyridines offer advantages over older calcium channel blockers because the second-generation drugs provide greater vascular selectivity and less direct myocardial depression.
尽管许多药物能有效控制糖尿病患者的高血压,但加重糖尿病进程并引发新并发症的风险可能会抵消血压降低带来的益处。本文讨论了糖尿病患者抗高血压治疗的现状,并重点关注钙通道阻滞剂的使用,这类药物能安全地降低血压,同时对糖尿病状态及相关医学并发症具有中性或有益作用。虽然钙通道阻滞剂和血管紧张素转换酶(ACE)抑制剂都是糖尿病高血压初始治疗的合适药物,但钙通道阻滞剂对葡萄糖稳态、脂质代谢和肾功能的有益作用支持将其作为ACE抑制剂的替代药物常规使用。在三类钙通道阻滞剂中,第二代二氢吡啶类药物比老一代钙通道阻滞剂具有优势,因为第二代药物具有更高的血管选择性和更低的直接心肌抑制作用。